Actinium Pharmaceuticals (ATNM) Restructuring Costs (2011 - 2012)
Actinium Pharmaceuticals (ATNM) posted quarterly Restructuring Costs of $2616.0 for Q3 2012, up 690.33% year-over-year from $331.0 in Q4 2011, and up 89.02% quarter-over-quarter from $1384.0 in Q2 2012.
Actinium Pharmaceuticals (ATNM) Restructuring Costs (2011 - 2012) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Restructuring Costs for 2 consecutive years, with $2616.0 the latest figure, recorded in Q3 2012.
- In Q3 2012, Restructuring Costs rose 690.33% year-over-year to $2616.0; the TTM figure through Sep 2012 stood at $5211.0 (changed N/A YoY), while the FY2011 annual figure was $337.0, down 27.68% from the prior year.
- Restructuring Costs climbed to $2616.0 in Q3 2012 per ATNM's latest filing, from $1384.0 in the prior quarter.
- Across five years, Restructuring Costs topped out at $2616.0 in Q3 2012 and bottomed at $205.0 in Q4 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - |
| 10 | Actinium Pharmaceuticals | 34.88 Mn | 34.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2012 | 2,616.00 |
| Jun 30, 2012 | 1,384.00 |
| Mar 31, 2012 | 1,006.00 |
| Dec 31, 2011 | 205.00 |
| Sep 30, 2011 | 331.00 |